ChinaBio® Investor Forum
March 19-20, 2009 | Hong Kong
A SPARC Forum event hosted by the Hong Kong Science and Technology Parks Corporation
Showcasing biotechnology from the Pearl River Delta™
The Pearl River Delta is a significant source of technology development in China. Hong Kong, Shenzhen and Guangzhou each have major centers of biotech development, including life science parks, leading institutions and universities, and companies creating novel technologies.
The ChinaBio® Investor Forum brings entrepreneurs and investors together in a unique platform that has enabled early and mid-stage life science companies in China to raise over $60M US as a result of our forums. VCs in attendance included Sofinnova, Mingly China Growth Fund, Bay City Capital, Lilly Asia Ventures, Fidelity Asia Ventures, Qiming Ventures, BioVeda China, HBM BioMed, Morningside, and many more. Plus many of the big pharma attended looking for new technologies, including Merck, Pfizer, Roche, Lilly, and others
Now, the ChinaBio® Investor Forum will be hosted in Hong Kong for the first time. 20 early stage biotechnology, diagnostics, medical device and services companies from throughout China will be presenting. Attendees will have the opportunity to screen these companies in a rapid two-day forum that also offers educational sessions on the state of the biotechnology industry and VC investment in China and Hong Kong from over 25 experts.
The SPARC Forum is a technology marketplace series hosted at Hong Kong Science Park for innovators to forge partnerships with industry leaders around the Pearl River Delta region and to facilitate commercialisation of their research. As the signature series organized by the Hong Kong Science and Technology Parks Corporation (HKSTP), the SPARC Forum addresses developing trends and issues facing technology research and commercialisation in various technology sectors. HKSTP is pleased to partner with ChinaBio® Accelerator to organize the ChinaBio® Investor Forum as a SPARC Forum event for the Life Science and Biotechnology sector. More information on the 2008 SPARC Forum is available at http://sparc.hkstp.org/HKSTPC/sparc/program-intro.jsp.
So join us at the ChinaBio® Investor Forum in Hong Kong on March 19 每 20, 2009 to see the best early stage life science companies in China and Hong Kong.
Why Attend:
Meet early and mid-stage companies seeking investment
Connect with VCs and other investors from the US and China
Understand the opportunities and challenges of the biotech industry in China and Hong Kong
Network with other entrepreneurs, industry executives and investors
Who Should Attend:
U.S. & China/Hong Kong VCs, fund managers and angel investors
Global pharma executives and business development managers
China & Hong Kong biotech entrepreneurs
Industry analysts, media, etc.
Format:
Two days packed with company presentations and informative sessions
Keynote speakers and panelists give insights and analysis of the China biotech industry
Entrepreneurs present business plans and then meet face-to-face with investors in breakout sessions
Multiple networking opportunities including the popular dinner reception on March 19
Top companies receive ※Most Promising§ Awards in the ceremony held on March 20
Topics:
State of China Biotech 每 where is biotech going in China & Hong Kong and how it will be impacted by the financial crisis?
Building a Biomedical Business in China 每 learn how to structure and build a successful biotech in China
Biomedical Research in Hong Kong 每 discover novel technologies being developed Hong Kong
From Research to Commercialization 每 how to take technologies from the lab and create revenue
Success Stories in Hong Kong 每 hear successful entrepreneurs and VCs tell how they did it
Partnering Opportunities in Greater China 每 meet pharma and service execs willing to partner with you
HKSTP as a Business Base - explore how Hong Kong Science and Technology Park can help make your business successful
笢恅
